Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.43 |
| ▸ | CNR1 | P21554 | 8/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
| ▸ | KLK1 | P06870 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757494 | 0.92 | CNR2 (0.42) | CNR2CNR1KLKB1KLK1MEN1 | |
| SCHEMBL5758877 | 0.92 | CNR2 (0.45) | CNR2CNR1KLKB1KLK1DRD2 | |
| SCHEMBL5758356 | 0.92 | PDE10A (0.43) | CNR2CNR1KLKB1KLK1ELANE | |
| SCHEMBL5760152 | 0.92 | CNR1 (0.43) | CNR2CNR1KLKB1KLK1LMNA | |
| SCHEMBL27624389 | 0.91 | CNR2 (0.42) | CNR2CNR1KLKB1KLK1DRD2 | |
| SCHEMBL5758836 | 0.90 | TP53 (0.48) | CNR2CNR1KLKB1KLK1MEN1 | |
| SCHEMBL5759860 | 0.90 | CNR2 (0.45) | CNR2CNR1KLKB1KLK1LMNA | |
| SCHEMBL5758190 | 0.89 | ELANE (0.49) | CNR2CNR1KLKB1KLK1ELANE | |
| SCHEMBL5757562 | 0.88 | CNR1 (0.49) | CNR2CNR1KLKB1KLK1KMT2A | |
| SCHEMBL5755575 | 0.88 | PDE10A (0.45) | CNR2CNR1KLKB1KLK1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | CNR2 2164/4885CNR1 2232/4885KLKB1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.